Comparative effects of different types of exercises on thyroid function and quality of life in patients with hypothyroidism

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202305810673587

Enrollment

Registered

2023-05-02

Start date

2022-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nutritional, Metabolic, Endocrine

Interventions

pharmacological treatment

resistance training plus pharmacological treatment

Progressive Resistance training

Combined aerobic and resistance exercises

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1- Female patients. 2- History of primary hypothyroidism (High TSH and low thyroid hormone level). 3- Controlled primary hypothyroidism (TSH between 0.2 to 4.6 mIU/L and free T4 between 0.8 to 1.8 ng/dL) in at least 6 months. 4- Their ages will be ranged from 35 to 45 years old. 5- They will be on thyroid hormone replacement therapy (e.g. Levothyroxine). 6- Their BMI will be from 25 to 35 Kg/m2. 7- All patients will be clinically and medically stable when attending the study.

Exclusion criteria

Exclusion criteria: 1- Secondary hypothyroidism. 2- Subclinical hypothyroidism (High TSH, normal thyroid hormone level). 3- Thyroiditis. 4- Pituitary disease (Low TSH, low thyroid hormone level). 5- Unstable cardiovascular problems like arrhythmia and heart failure. 6- Diabetes. 7- Chronic chest disease. 8- Women on contraceptive pills. 9- Patients on medications affecting muscle power as steroids. 10- Peripheral vascular diseases. 11- Pregnancy & lactation. 12- Known patients with hypovitaminosis D or hypocalcemia or biotin supplements.

Design outcomes

Primary

Measure	Time frame
Thyroid hormones (TSH and T4): •Venous blood samples (5 ml) will be collected from each patient in all groups . •Medications affecting thyroid hormones should be stopped 3 days before the testing. •Serums of collected samples will separated from plasma by centrifuge pump in duration of 10 min ;The quality of life will be assessed using Short form health survey (SF-12). The SF-12 contains 12 items. All SF-12 items came from the SF-36. It includes eight dimensions: physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems and mental health	—

Measure

Time frame

Thyroid hormones (TSH and T4): •Venous blood samples (5 ml) will be collected from each patient in all groups . •Medications affecting thyroid hormones should be stopped 3 days before the testing. •Serums of collected samples will separated from plasma by centrifuge pump in duration of 10 min ;The quality of life will be assessed using Short form health survey (SF-12). The SF-12 contains 12 items. All SF-12 items came from the SF-36. It includes eight dimensions: physical functioning, role limitations due to physical health problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems and mental health

—

Secondary

Measure	Time frame
Lipid parameters including Total Cholesterol, Triglycerides, HDL and LDL will be measured	—

Countries

Egypt

Contacts

Public ContactAhmad Mahdy

Coordinator

ahmed.mahdy@pt.cu.edu.eg+201007056624

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026